Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MTPH Stock Overview
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally.
Midatech Pharma Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.087 |
52 Week High | UK£0.30 |
52 Week Low | UK£0.082 |
Beta | 1.54 |
1 Month Change | -14.63% |
3 Month Change | -28.57% |
1 Year Change | -70.09% |
3 Year Change | -91.42% |
5 Year Change | -99.58% |
Change since IPO | -99.84% |
Recent News & Updates
Shareholder Returns
MTPH | GB Biotechs | GB Market | |
---|---|---|---|
7D | -5.4% | 1.2% | 1.4% |
1Y | -70.1% | -41.7% | -9.5% |
Return vs Industry: MTPH underperformed the UK Biotechs industry which returned -40.8% over the past year.
Return vs Market: MTPH underperformed the UK Market which returned -6.7% over the past year.
Price Volatility
MTPH volatility | |
---|---|
MTPH Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 5.4% |
10% most volatile stocks in GB Market | 10.6% |
10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: MTPH is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MTPH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 20 | Stephen Stamp | https://www.midatechpharma.com |
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Midatech Pharma Fundamentals Summary
MTPH fundamental statistics | |
---|---|
Market Cap | UK£8.62m |
Earnings (TTM) | -UK£5.46m |
Revenue (TTM) | UK£578.00k |
14.9x
P/S Ratio-1.6x
P/E RatioIs MTPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MTPH income statement (TTM) | |
---|---|
Revenue | UK£578.00k |
Cost of Revenue | UK£4.65m |
Gross Profit | -UK£4.08m |
Other Expenses | UK£1.38m |
Earnings | -UK£5.46m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.055 |
Gross Margin | -705.19% |
Net Profit Margin | -944.64% |
Debt/Equity Ratio | 0% |
How did MTPH perform over the long term?
See historical performance and comparisonValuation
Is MTPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MTPH?
Other financial metrics that can be useful for relative valuation.
What is MTPH's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | UK£8.62m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MTPH's PS Ratio compare to its peers?
MTPH PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 78.6x | ||
RENE ReNeuron Group | 57.8x | 77.7% | UK£15.8m |
PBX ProBiotix | 31.9x | n/a | UK£26.2m |
DEST Destiny Pharma | 222.8x | n/a | UK£30.1m |
TRX Tissue Regenix Group | 1.9x | 27.2% | UK£31.6m |
MTPH Midatech Pharma | 14.9x | n/a | UK£8.6m |
Price-To-Sales vs Peers: MTPH is good value based on its Price-To-Sales Ratio (14.9x) compared to the peer average (78.6x).
Price to Earnings Ratio vs Industry
How does MTPH's PE Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: MTPH is good value based on its Price-To-Sales Ratio (14.9x) compared to the UK Biotechs industry average (18.3x)
Price to Sales Ratio vs Fair Ratio
What is MTPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 14.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MTPH's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MTPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MTPH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
17.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Midatech Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Midatech Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Midatech Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Midatech Pharma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-0.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTPH is currently unprofitable.
Growing Profit Margin: MTPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: MTPH has a negative Return on Equity (-52.24%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Midatech Pharma's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MTPH's short term assets (£11.8M) exceed its short term liabilities (£1.8M).
Long Term Liabilities: MTPH's short term assets (£11.8M) exceed its long term liabilities (£620.0K).
Debt to Equity History and Analysis
Debt Level: MTPH is debt free.
Reducing Debt: MTPH has no debt compared to 5 years ago when its debt to equity ratio was 4.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MTPH has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 15.1% each year.
Discover healthy companies
Dividend
What is Midatech Pharma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MTPH has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Stephen Stamp (59 yo)
2.75yrs
Tenure
UK£328,867
Compensation
Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Midatech Pharma plc since September 9, 2019. He serves as Chief Executive Officer at Midatech Pharma plc since March 31, 2020 and serv...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD399.62K) is about average for companies of similar size in the UK market ($USD334.17K).
Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: MTPH's management team is considered experienced (2.1 years average tenure).
Board Members
Experienced Board: MTPH's board of directors are considered experienced (7.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.4%.
Top Shareholders
Company Information
Midatech Pharma plc's employee growth, exchange listings and data sources
Key Information
- Name: Midatech Pharma plc
- Ticker: MTPH
- Exchange: AIM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£8.618m
- Shares outstanding: 98.49m
- Website: https://www.midatechpharma.com
Number of Employees
Location
- Midatech Pharma plc
- 1 Caspian Point
- Caspian Way
- Cardiff
- South Glamorgan
- CF10 4DQ
- United Kingdom
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/30 00:00 |
End of Day Share Price | 2022/06/30 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.